A Multicentre, Open-label, Interventional, Pilot Trial to Assess the Performance and Tolerance of mRDX-02-17 Dermal Filler in the Facial Rejuvenation
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Enrollment
- 39
- Locations
- 2
- Primary Endpoint
- Wrinkle Severity Rating Scale (WSRS) Score
Study Overview
Brief Summary
mRDX-02-17 is a device for facial beauty care composed of hyaluronic acid in a concentration of 1.5% (p/v), as a functional ingredient, recommended for the correction and treatment of wrinkles and dermal depressions.
The primary hypothesis of this clinical investigation is that, at 30 days after the 60 days of treatment with mRDX-02-17, the mean WSRS score assessed by the investigator will decrease with at least 0.5 points compared to baseline evaluation.
Detailed Description
Minimally invasive procedures (injectable dermal fillers) are among the techniques preferred by an increasing number of specialists in Aesthetics due to their clinical performance regarding volume restoration and favorable safety profile.
An evaluation of pre-clinical data was performed before the clinical investigation design.
Similar dermal fillers have been used in several clinical investigations in humans with a good rate of clinical success and good safety profiles.
During January - March 2018, review of the scientific literature was performed, to find similar investigations to determine the minimal clinically significant difference between Baseline and a period of 30 days after the end the treatment.
Considering the exploratory nature of this study and the fact that this investigation is first-in-human, the clinical investigation is designed to have a number of 7 study visits and a treatment period of 60 days.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 35 Years to 65 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Men or women with age > 35 and ≤ 65 years;
- •Subjects seeking tissue augmentation treatment on the face;
- •Subjects willing to receive HA Filler for one and/or more mimetic and/or superficial facial wrinkles located in the facial area including periocular area;
- •Subjects willing to receive HA Filler for one and/or more mimetic and/or superficial facial wrinkles;
- •Subjects willing to provide signed informed consent to clinical investigation participation.
Exclusion Criteria
- •Use of aspirin and antiplatelet agents a week prior to treatment;
- •Pregnant or lactating women;
- •Subjects with a history of allergy or hypersensitivity to the HA or to other ingredients of the dermal filler;
- •Subjects with hypersensitivity to salicylic acid or any of its derivates;
- •Subjects with any dermal systemic pathologies, such as systemic lupus erythematosus, psoriasis, scleroderma etc.;
- •Subjects presenting bleeding disorders in the past or present;
- •Subjects taking or having indications for anticoagulant therapy;
- •Use of concomitant treatments or procedures aimed to improve skin rejuvenation over the last six months before the clinical investigation enrolment, such as chemical peeling, dermabrasion, laser resurfacing;
- •Subjects suffering from infectious diseases including herpes simplex virus infection, active hepatitis or human immunodeficiency virus;
- •Subjects suffering from eczema, acne, and keloids;
- •Subjects with any cutaneous manifested infection, disease or alteration;
- •Subjects at risk in term of precautions, warnings, and contra-indications referred in the package insert of the clinical investigation device;
- •Subjects with any facial aesthetic surgery in the preceding 12 months before the clinical investigation enrolment;
- •Subjects with any active irritation or inflammation in the target areas of injection;
- •Subjects who received botulinum toxin A injections in the face in the preceding 6 months;
- •Subjects unlikely to cooperate in the clinical investigation or to comply with the treatment or with the clinical investigation visits;
- •Subjects with solar activity, such as prolonged exposure to the sun, UV rays and extreme conditions of heat for at least a week after the treatment
- •Direct or indirect contact with quaternary ammonium salts during the investigation
- •Subjects participating in another clinical investigation or treated with another HA filler with the same indications at the same time or within the preceding 30 days.
Arms & Interventions
mRDX-02-17
mRDX-02-17 is a dermal filler recommended for correction and treatment of wrinkles and dermal depressions, which are administered by intradermal injections. It encourages repair and restructuring of skin tissue, reducing the signs of aging and has the following indications:
- Hypotrophic tissues
- Tissue hypotonicity
- Crow's feet
- Glogau III - IV
- Fiztpatrick I - VI
- WSRS (Wrinkle Severity Ranking Scale): 2-5
Intervention: mRDX-02-17 (Device)
Outcomes
Primary Outcomes
Wrinkle Severity Rating Scale (WSRS) Score
Time Frame: 90 days
The Wrinkle Severity Rating Scale is a 5-grade score scale, evaluating the severity of the facial wrinkles and comprising descriptive answers, numbered from 1 to 5. The best possible answer is 1 (no folds, continuos skin line) and the worst possible answer is 5 (extremely deep and long folds). This scale is evaluated by an investigator
Secondary Outcomes
- Treatment Satisfaction(30 and 90 days)
- Choice of Recommendation(90 days)
- Global Aesthetic Improvement Scale (GAIS) Score(15, 30, 45, 60 and 90 days)
- Wrinkle Severity Rating Scale (WSRS) Score(0, 15, 30, 45, 60 and 90 days)